Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Brian Daniels
AddedMar 31, 2024
UpdatedMay 31, 2026
Brian Daniels

Brian Daniels

Board Member, Inipharm

Crunchbase

Brian Daniels's Career

Inipharm
Inipharm

Seattle, WA, US

Board Member· Board
Nohla Therapeutics
Nohla Therapeutics

Seattle, WA, US

Board Member· Board
Spyryx Biosciences
Spyryx Biosciences

Durham, NC, US

Board Member· Board
RareCyte
RareCyte

Seattle, WA, US

Board Member· Board
Artiva Biotherapeutics
Artiva Biotherapeutics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Brian Daniels's Career

Inipharm
Inipharm
Public$35M92018Seattle, WA, US
Board Member· Board

Leadership at Inipharm

Michael GallatinMichael GallatinBoard Member
Bob BalteraBob BalteraBoard Member
Brian FarmerBrian FarmerCo-Founder

Similar to Inipharm

InpharmDInpharmDAtlanta, GA, USClinical Answersest. 2018InpharmDAtlanta, GA, US · est. 2018

Curated, evidence-based clinical answers for healthcare providers.

Seed · $6.2M19
HepanovaHepanovaGaithersburg, MD, USTherapeuticsest. 2014HepanovaGaithersburg, MD, US · est. 2014

Hepanova, Inc.: A global pharmaceutical firm innovating therapeutics for chronic liver diseases since 2014.

Seed · $10.2M11
Avalyn PharmaAvalyn PharmaSeattle, WA, USPharmaceuticalsest. 2011Avalyn PharmaSeattle, WA, US · est. 2011

Avalyn Pharma Inc.: Developing innovative therapies for Idiopathic Pulmonary Fibrosis.

Series C · $272.5M27
Inception SciencesInception SciencesSan Diego, CA, USPharmaceuticalsest. 2011Inception SciencesSan Diego, CA, US · est. 2011

Inception Sciences: Developing and marketing high-value pharmaceutical therapies for chronic diseases in the US.

Series A · $20M30
Nohla Therapeutics
Nohla Therapeutics
Acquired$120.5M02015Seattle, WA, US
Board Member· Board

Leadership at Nohla Therapeutics

Colleen DelaneyColleen DelaneyFounder
Michael SistenichMichael SistenichBoard Member
Kathleen FanningKathleen FanningBoard Member
Lawrence Bernard GozlanLawrence Bernard GozlanBoard Member
Steve GillisSteve GillisBoard Member
Spyryx Biosciences
Spyryx Biosciences
Series A$18.2M302013Durham, NC, US
Board Member· Board

Leadership at Spyryx Biosciences

Christy ShafferChristy ShafferBoard Member
Robert TarranRobert TarranFounder
Roger JeffsRoger JeffsBoard Member
Tim ShannonTim ShannonBoard Member
John C TaylorJohn C TaylorCEO

Similar to Spyryx Biosciences

SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
SynspiraSynspiraFramingham, MA, USBiotechest. 2017SynspiraFramingham, MA, US · est. 2017

Synspira Therapeutics: A clinical-stage biotech firm innovating treatments for cystic fibrosis and rare diseases.

Series B · $25.2M8
PulmatrixPulmatrixLexington, MA, USTherapeuticsest. 2003PulmatrixLexington, MA, US · est. 2003

Pulmatrix, Inc.: A US-based biotech firm specializing in therapies for chronic respiratory diseases.

Public · $148.4M24
Spirrow TherapeuticsSpirrow TherapeuticsBoston, MA, USLung Restorationest. 2018Spirrow TherapeuticsBoston, MA, US · est. 2018

Spirrow Therapeutics: Innovating lung restoration for ARDS-affected babies using proprietary methods.

Angel · $256k6
RareCyte
RareCyte
Public$76M782009Seattle, WA, US
Board Member· Board

Leadership at RareCyte

Andy SchwabAndy SchwabBoard Member
Jan GarfinkleJan GarfinkleBoard Member
Frank WitneyFrank WitneyBoard Member
Daniel R. MarshakDaniel R. MarshakBoard Member
Joseph VictorJoseph VictorBoard Member
David S. KabakoffDavid S. KabakoffBoard Member
Artiva Biotherapeutics
Artiva Biotherapeutics
Series B$198M782019San Diego, CA, US
Board Member· Board

Leadership at Artiva Biotherapeutics

Laura StoppelLaura StoppelBoard Member
Peter FlynnPeter FlynnFounder
Linda KozickLinda KozickBoard Member
Fred AslanFred AslanCEO

Brian Daniels's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Brian Daniels

Kevin ForrestKevin ForrestCo-Founder · Cidara TherapeuticsRenato SkerljRenato SkerljCo-Founder · X4 PharmaceuticalsCasey CunninghamCasey CunninghamBoard Member · TerapioKen ChaplinKen ChaplinBoard Member · DoximityThomas P. KennedyThomas P. KennedyCo-Founder · JSK TherapeuticsJonathan SackierJonathan SackierBoard Member · NovaTract Surgical